Pfizer Inc said on Tuesday that along with partner BioNTech Se it was developing a booster shot to protect against COVID-19 variants.
“We are already laying the groundwork to respond quickly if a variant of SARS-CoV-2 shows evidence of escaping immunity by our vaccine,” Pfizer said in an email to Reuters.
However, the company added that studies needed to evaluate the booster shot are yet to be determined in agreement with regulators.
The story was first reported by Bloomberg News.
Moderna Inc, whose vaccine has also been authorized for emergency use in the United States, had said on Monday it would test a new booster shot aimed at the South African variant of the coronavirus after concluding the antibody response could be diminished.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.